Human papillomavirus vaccination in the European Union/European Economic Area and globally: a moral dilemma.
Human papillomavirus vaccination in the European Union/European Economic Area and globally: a moral dilemma.
复制标题
DOI：
10.2807/1560-7917.es.2021.26.50.2001659
复制
发表时间：
2021-12
期刊：
影响因子：
--
通讯作者：
Pastore Celentano L
中科院分区：
文献类型：
--
作者：
Colzani E;Johansen K;Johnson H;Pastore Celentano L
虽然许多欧洲联盟/欧洲经济区（EU/EEA）国家最近将人乳头瘤病毒（HPV）疫苗接种范围扩大到男孩，但目前受HPV严重影响的低收入和中等收入国家（LMIC）女孩的HPV疫苗供应有限。在全球范围内，约有50%的国家采用了HPV疫苗接种。一些宫颈癌高负担的低收入和中等收入国家尚未引入HPV疫苗接种，或疫苗接种覆盖率未达到最佳水平。虽然世卫组织在2018年发出了消除宫颈癌的呼吁，但目前预计全球HPV疫苗短缺将至少持续到2024年。我们审查了欧盟/欧洲经济区国家的国家政策和世界卫生组织（世卫组织）免疫战略咨询专家组的建议，以讨论当前的挑战和剂量节约选择。一些欧盟/欧洲经济区国家已经将HPV疫苗接种范围扩大到男孩，欧洲癌症组织已经发布了一项决议，旨在消除所有与HPV相关的男性和女性癌症。欧洲疾病预防和控制中心在其2020年指南中得出结论，将常规疫苗接种扩大到男孩的成本效益取决于几个具体情况的因素。将人乳头瘤病毒疫苗接种扩大到欧盟/欧洲经济区国家的男孩可能会影响全球疫苗的供应。在COVID-19大流行后时期可考虑采取临时剂量节约方案。
While many European Union/European Economic Area (EU/EEA) countries recently expanded human papillomavirus (HPV) vaccination to boys, HPV vaccine supply is currently limited for girls in low- and middle-income countries (LMIC) that are severely affected by HPV. Globally, about 50% of countries have introduced HPV vaccination. Some LMIC with high burden of cervical cancer have not yet introduced HPV vaccination, or are reaching suboptimal vaccination coverage. While WHO issued a call for cervical cancer elimination in 2018, a global shortage of HPV vaccines is currently predicted to last at least until 2024. We reviewed national policies of EU/EEA countries and recommendations of the World Health Organization (WHO) Strategic Advisory Group of Experts on immunisation to discuss current challenges and dose-sparing options. Several EU/EEA countries have extended HPV vaccination to boys and the European Cancer Organisation has issued a resolution for elimination of all HPV-associated cancers in both sexes. The European Centre for Disease Prevention and Control concluded in its 2020 guidance that cost-effectiveness of extending routine vaccination to boys depends on several context-specific factors. The extension of HPV vaccination to boys in EU/EEA countries may affect global availability of vaccines. Temporary dose-sparing options could be considered during the COVID-19 post-pandemic period.